Description

Zolacid (Zoledronic Acid) Concentrate for Infusions 4 mg/5 ml Vial 5 ml №1

Ingredients:

Each vial contains 4 mg of zoledronic acid in 5 ml of concentrate.

Dosage:

The recommended dosage of Zolacid for adults is 4 mg infused over at least 15 minutes every 6 months.

Indications:

Zolacid is indicated for the treatment and prevention of osteoporosis in postmenopausal women, for the treatment of osteoporosis in men, and for the treatment of Paget’s disease of bone.

Contraindications:

Do not use Zolacid if you have low levels of calcium in your blood or if you are allergic to zoledronic acid.

Directions:

Zolacid should be administered by a healthcare professional as an intravenous infusion. It is important to follow the recommended dosage and infusion rate to minimize the risk of adverse reactions.

Scientific Evidence:

Zoledronic acid, the active ingredient in Zolacid, is a bisphosphonate that inhibits bone resorption. Studies have shown that zoledronic acid is effective in increasing bone mineral density and reducing the risk of fractures in patients with osteoporosis. Research published in the Journal of Bone and Mineral Research demonstrated the efficacy of zoledronic acid in reducing vertebral fractures by 70% over 3 years.

Additional Information:

Zolacid has been well-studied in clinical trials, showing significant improvements in bone health and a good safety profile. It is important to monitor calcium levels during treatment with Zolacid and to ensure an adequate intake of vitamin D to support bone health.

Overall, Zolacid (zoledronic acid) concentrate for infusions is a potent treatment option for osteoporosis and Paget’s disease of bone, supported by robust scientific evidence and clinical trials. Its mechanism of action in inhibiting bone resorption makes it a valuable therapeutic agent in the management of these conditions.